We report here the interesting case of a 76-year-old man with severe proteinuria who was diagnosed with systemic mastocytosis accompanied by a clonal non-mast-cell lineage haematological disorder (a non-secretory plasma cell dyscrasia). This is a unique report of systemic mastocytosis with a non-secretory plasma cell dyscrasia and nephrotic syndrome. The pathophysiological relevance between these entities along with the probability of occult amyloidosis is discussed.

Keywords:
Myeloproliferative disease, Occult amyloidosis, Plasma cell dyscrasia, Renal impairment, Systemic mastocytosis
1.
Furie B, Voo L, McAdam KP, Furie BC: Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981;304:827-830.
2.
Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC: Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885-1887.
3.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 56-57.
4.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008, pp 202-212.
5.
George TI, Horny HP: Systemic mastocytosis. Hematol Oncol Clin North Am 2011;25:1067-1083.
6.
Horny HP: Mastocytosis, an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol 2009;132:438-447.
7.
Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana L, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis in a series of 113 patients. Blood 2006;108:2366-2372.
8.
Tan A, Westerman D, McArthur G, Lynch K, Waring P, Dobrovic A: Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006;52:2250-2257.
9.
Poliantseva LR, Klepikov PV, Varshavskiĭ VA: Nephrotic syndrome in a patient with systemic mastocytosis. Klin Med (Mosk) 1983;61:115-119.
10.
Lal SM, Brooks CS, Luger AM, Davenport JG, Weber RD, Loy TS, Haibach HH: Systemic mastocytosis associated with membranous nephropathy and peripheral neuropathy. Am J Kidney Dis 1988;12:538-543.
11.
Matsuzaki H, Yoshida M, Akahoshi Y, Kuwahara K, Satou T, Takatsuki K: Pseudo-nonsecretory multiple myeloma with light chain deposition disease. Acta Haematol 1991;85:164-168.
12.
Gafumbegete E, Richter S, Jonas L, Nizze H, Makovitzky J: Nonsecretory multiple myeloma with amyloidosis. A case report and review of the literature. Virchows Arch 2004;445:531-536.
13.
Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, Cabral H, Dember LM, Sanchorawala V, Connors LH, Falk RH, Skinner M: Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005;12:210-215.
14.
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz M: Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010;116:5126-5129.
15.
Rosenstein ED, Itzkowitz SH, Penziner AS, Cohen JI, Mornaghi RA: Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med 1983;143:597-599.
16.
Hachulla E, Grateau G: Diagnostic tools for amyloidosis. Joint Bone Spine 2002;69:538-545.
17.
Bogov B, Lubomirova M, Kiperova B: Biopsy of subcutaneous fatty tissue for diagnosis of systemic amyloidosis. Hippokratia 2008;12:236-239.
18.
Motwani P, Kocoglu M, Lorsbach RB: Systemic mastocytosis in association with plasma cell dyscrasias: report of a case and review of the literature. Leuk Res 2009;33:856-859.
19.
Sotlar K, Saeger W, Stellmacher F, Stahmer J, Jäckle S, Valent P, Horny HP: ‘Occult' mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol 2006;59:875-878.
20.
Stellmacher F, Sotlar K, Balleisen L, Valent P, Horny HP: Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma 2004;45:801-805.
21.
Hagen W, Schwarzmeier J, Walchshofer S, Zojer N, Chott A, Sillaber C, Ackermann J, Simonitsch I, Bühring HJ, Drach J, Lechner K, Horny HP, Valent P: A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol 1998;76:167-174.
22.
Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM: An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 2012;12:459-462.
23.
Pullarkat S, Sedarat F, Paquette R, Said J: Systemic mastocytosis with plasma cell dyscrasia: report of a case. Leuk Res 2008;32:1160-1163.
24.
Diamantidis MD, Myrou AD, Kaiafa GD, Kaloutsi V, Karayannopoulou G, Theodoridis A, Adamidou A, Papadopoulos A, Grekas D: Aggressive systemic mastocytosis associated with mesangioproliferative glomerulonephritis. Acta Haematol 2010;125:153-159.
25.
Horny HP, Sotlar K, Sperr WR, Valent P: Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-608.
26.
Stoecker MM, Wang E: Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review. Arch Pathol Lab Med 2012;136:832-838.
27.
Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, Tefferi A: Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009;114:3769-3772.
28.
Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, Eclache V, Laroche L, Lortholary P, Raphaël M, Guillevin L, Lortholary O: Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-1097.
29.
Tefferi A, Li CY, Butterfield JH, Hoagland HC: Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001;344:307-309.
30.
Pardanani A: Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:401-411.
31.
Pardanani A: How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013;121:3085-3094.
32.
Valent P, Sperr W, Akin C: How I treat patients with advanced systemic mastocytosis. Blood 2010;116:5812-5817.
33.
Blauvelt A, Kerdel FA: Intravenous corticosteroids for systemic mastocytosis. Arch Dermatol 1991;127:1586.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.